Idanuz

Icatibant, the active ingredient in Idanuz, is a bradykinin B2 receptor antagonist presented as a solution for injection for subcutaneous use. It treats acute attacks of hereditary angioedema in patients with a confirmed diagnosis. GNH USA supplies Idanuz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Idanuz is a bradykinin B2 receptor antagonist indicated for the treatment of hereditary angioedema attacks. - Acute hereditary angioedema: provides rapid relief of swelling episodes and reduces disease burden during attacks.

Common adverse reactions are usually mild and related to the injection site or transient systemic responses.

Common Side Effects: - Injection site pain: discomfort at the subcutaneous injection site. - Redness or erythema: localized skin reddening. - Swelling at injection site: mild, temporary edema. - Nausea: occasional feeling of queasiness. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Angioedema of the face or throat: may compromise airway. - Hypotension: sudden drop in blood pressure. - Severe injection site necrosis: tissue damage at the site. - Thrombocytopenia: low platelet count observed in rare cases.

Before using Idanuz, consider the following safety measures. - Pregnancy: safety not established; use only if potential benefit justifies the risk. - Breastfeeding: unknown excretion; weigh benefits against possible infant exposure. - Renal impairment: no dosage adjustment required, but monitor for accumulation. - Concomitant ACE inhibitors: may increase risk of angioedema; assess necessity. - Hypersensitivity: discontinue immediately if signs of allergic reaction appear. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other agents that influence bradykinin pathways or immune responses.

Major Interactions (Avoid): - ACE inhibitors: can raise bradykinin levels and heighten angioedema risk. - Neprilysin inhibitors (e.g., sacubitril): may increase bradykinin concentrations, potentially reducing icatibant efficacy.

Moderate Interactions (Monitor Closely): - Antihistamines: may mask early signs of an allergic reaction. - Systemic corticosteroids: could alter assessment of swelling severity. - Other subcutaneous injections at the same site: may increase local irritation or infection risk.